Advaxis Will Present at the Sidoti 2011 Semi-Annual New York Micro-Cap Conference

The New York Grand Hyatt Hotel | January 10th at 10:40 ET | Estate 7 Plymouth Room

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Chairman / Chief Executive Officer Thomas Moore of Advaxis, Inc., (OTCBB: ADXS) the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company will be presenting at the Sidoti 2011 Semi-Annual, New York Micro-Cap Conference.

Mr. Moore will present on January 10, 2011 at 10:40am EST in the Estate 7 Plymouth room of the Grand Hyatt in New York. Some topics to be discussed in his investor presentation will be the progress of the company’s phase II clinical trials in cervical dysplasia and cervical cancer.

About the Sidoti Semi-Annual New York Micro-Cap Conference

Sidoti & Company, LLC Micro-Cap Conferences afford companies a chance to “strut their stuff” in front of a group of savvy institutional investors — declaring what their organizations are all about, what innovations they have developed and/or capitalized on, how they stand out from their rivals and why the investment community should pay attention to them. Sidoti introduces companies that boast sound fundamentals and intriguing stories, show fast growth and profitability, or otherwise hold great promise; yet, are largely unknown to investors. At their last conference, nearly every major institutional investor in the micro-cap sector was present - over 400 attendees in total. For more information please visit: http://microcap.sidoti.com/.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, four (4) clinical trials – two (2) in progress and two (2) to be started – and two (2) Cooperative Research and Development Agreements (CRADA) with the National Cancer Institute and the Department of Homeland Security, respectively. The Company conducts direct and strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the University of Pittsburgh and the University of British Columbia.

Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir
Executive Director
732.545.1590 (Office)
732.545.1084 (FAX)
[email protected]
or
Advaxis, Incorporated
Diana Moore
Analyst
732.545.1590 (Office)
732.545.1084 (FAX)
[email protected]

KEYWORDS:   United States  North America  New Jersey  New York

INDUSTRY KEYWORDS:   Seniors  Women  Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Finance  Teens  Consumer  Family  Gay & Lesbian  General Health  Men

MEDIA:

Logo
 Logo

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.